A Phase II Study of MLN8237 Alone and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2017
At a glance
- Drugs Alisertib (Primary) ; Rituximab (Primary)
- Indications B cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 15 Jul 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.
- 16 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 10 Dec 2014 Planned primary completion date changed from 1 Jun 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.